GLW
50
-5
MCO
65
-2
CA
24
-12
FAST
45
-3
ZION
50
-7
COST
51
-2
JNPR
59
-3
MTB
49
-6
DD
50
-2
KLAC
57
-2
AMAT
53
-4
ISRG
63
-3
CMG
60
-3
EXPD
53
-6
MCHP
42
-4
NOC
50
3
PCAR
46
-3
MO
39
-2
FRT
41
-4
GOOG
71
2
GLW
50
-5
MCO
65
-2
CA
24
-12
FAST
45
-3
ZION
50
-7
COST
51
-2
JNPR
59
-3
MTB
49
-6
DD
50
-2
KLAC
57
-2
AMAT
53
-4
ISRG
63
-3
CMG
60
-3
EXPD
53
-6
MCHP
42
-4
NOC
50
3
PCAR
46
-3
MO
39
-2
FRT
41
-4
GOOG
71
2
Financhill
Back

Lumos Pharma Stock Price Chart

Invest in the Next Big AI Disruptor Today

Learn More
Sell
42

LUMO
Lumos Pharma

Last Price:
3.57
Seasonality Move:
-0.8%

7 Day Trial

ALL ACCESS PASS

$ 7

The Fed Just Cut Rates-Here's Alex Green's $1 Million AI Stock Picks

Watch Alex Green's breakdown and discover the next big AI winners!
  • The current trend is moderately bearish and LUMO is experiencing selling pressure, which indicates risk of future bearish movement.

Lumos Pharma Price Chart Indicators

Moving Averages Level Buy or Sell
8-day SMA: 3.86 Sell
20-day SMA: 3.81 Sell
50-day SMA: 3.07 Buy
200-day SMA: 2.79 Buy
8-day EMA: 3.82 Sell
20-day EMA: 3.74 Sell
50-day EMA: 3.29 Buy
200-day EMA: 2.95 Buy

Lumos Pharma Technical Analysis Indicators

Chart Indicators Level Buy or Sell
MACD (12, 26): 0.17 Buy
Relative Strength Index (14 RSI): 48.82 Sell
Chaikin Money Flow: -83543 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (3.69 - 3.97) Sell
Bollinger Bands (100): (1.86 - 3.46) Buy

Lumos Pharma Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):

Technical Analysis for Lumos Pharma Stock

Is Lumos Pharma Stock a Buy?

  • Lumos Pharma share price is 3.59 while LUMO 8-day simple moving average is 3.86, which is a Sell signal.
  • The stock price of LUMO is 3.59 while Lumos Pharma 20-day SMA is 3.81, which makes it a Sell.
  • Lumos Pharma 50-day simple moving average is 3.07 while LUMO share price is 3.59, making it a Buy technically.
  • LUMO stock price is 3.59 and Lumos Pharma 200-day simple moving average is 2.79, creating a Buy signal.

LUMO Technical Analysis vs Fundamental Analysis

Sell
42
Lumos Pharma (LUMO) is a Sell

Is Lumos Pharma a Buy or a Sell?

  • Lumos Pharma stock is rated a Sell
    The current Lumos Pharma [LUMO] share price is $3.59. The Score for LUMO is 42, which is 16% below its historic median score of 50, and infers higher risk than normal.

Lumos Pharma Stock Info

Market Cap:
29.17M
Price in USD:
3.59
Share Volume:
119.27K

Lumos Pharma 52-Week Range

52-Week High:
4.55
52-Week Low:
1.37
Sell
42
Lumos Pharma (LUMO) is a Sell

Lumos Pharma Share Price Forecast

  • What is the Lumos Pharma stock price today?
    The Lumos Pharma stock price is 3.59 USD today.
  • Will LUMO stock go up or go down?
    Lumos Pharma> share price is forecast to RISE/FALL based on technical indicators
  • Is Lumos Pharma overvalued?
    According to simple moving average, exponential moving average, oscillators, and other technical indicators, Lumos Pharma is overvalued.

Is Lumos Pharma Stock a Buy?

  • Lumos Pharma share price is 3.59 while LUMO 8-day exponential moving average is 3.82, which is a Sell signal.
  • The stock price of LUMO is 3.59 while Lumos Pharma 20-day EMA is 3.74, which makes it a Sell.
  • Lumos Pharma 50-day exponential moving average is 3.29 while LUMO share price is 3.59, making it a Buy technically.
  • LUMO stock price is 3.59 and Lumos Pharma 200-day simple moving average is 2.95, creating a Buy signal.

Fundamental Analysis of Lumos Pharma

Is Lumos Pharma a good investment?

  • Analysts estimate an earnings increase this quarter of $0.32 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.26 per share, and an increase next year of $1.41 per share.

Technical Analysis of Lumos Pharma

Should I short Lumos Pharma stock?

* Lumos Pharma stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.